CSCO 2026 | Professor Lang He: China’s First CSCO Cancer Pain Guidelines Released, Advancing Comprehensive Cancer Pain Management Nationwide

CSCO 2026 | Professor Lang He: China’s First CSCO Cancer Pain Guidelines Released, Advancing Comprehensive Cancer Pain Management Nationwide

During the 2026 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), the first-ever CSCO cancer pain guidelines, the CSCO Guidelines for the Diagnosis and Treatment of Cancer Pain, were officially released, providing clinicians with standardized guidance that integrates the latest advances with the characteristics of clinical practice in China. Cancer pain remains highly prevalent in China, while the quality of its management varies considerably across different levels of healthcare institutions. The release of these new guidelines therefore comes at a particularly important time.
ESMO Voices from China | Professor Anwen Xiong: First-in-Class PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009 — Structural Innovation to Overcome Treatment Challenges in Advanced NSCLC

ESMO Voices from China | Professor Anwen Xiong: First-in-Class PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009 — Structural Innovation to Overcome Treatment Challenges in Advanced NSCLC

In recent years, immunotherapy for advanced non-small cell lung cancer (NSCLC) has evolved from the era of programmed cell death protein 1 (PD-1) monoclonal antibodies into the era of Immunotherapy 2.0, represented by bispecific antibodies. However, improving the objective response rate (ORR) while maintaining a favorable safety profile remains a major unmet clinical challenge.
2026 IFSC | Professor Abdullah Khan: Human Bone Marrow Organoids—A Novel In Vitro Platform for Precision Development in Hematologic Malignancies

2026 IFSC | Professor Abdullah Khan: Human Bone Marrow Organoids—A Novel In Vitro Platform for Precision Development in Hematologic Malignancies

Basic stem cell research, regenerative medicine, cell therapy, and the clinical application of research guidelines are among the most closely watched frontiers in hematology and translational medicine worldwide. With these topics at its core, The 10th International Forum on Stem Cells (IFSC) brought together leading experts and scholars from around the world to explore scientific discoveries and technological innovations, showcase the latest advances in basic, clinical, and translational hematopoietic stem cell research, and promote collaborative innovation across the global stem cell field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Abdullah Khan to share his latest research findings and academic insights on “Human Bone Marrow Organoids: A New Experimental Platform for Precision Development in Hematologic Malignancies.” The key points are presented below for our readers.
2026 IFSC | Professor Ari Melnick: Epigenetic Mechanisms of Stem-Like Plasticity in B-Cell Lymphomas and Targeted Therapeutic Strategies

2026 IFSC | Professor Ari Melnick: Epigenetic Mechanisms of Stem-Like Plasticity in B-Cell Lymphomas and Targeted Therapeutic Strategies

Basic stem cell research, regenerative medicine, cell therapy, and the clinical application of research guidelines are among the most closely watched frontiers in hematology and translational medicine worldwide. With these topics at its core, The 10th International Forum on Stem Cells (IFSC) brought together leading experts and scholars from around the world to explore scientific discoveries and technological innovations, showcase the latest advances in basic, clinical, and translational hematopoietic stem cell research, and promote collaborative innovation across the global stem cell field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Ari Melnick, Director of the Josep Carreras Leukaemia Research Institute in Spain, to share his latest research findings and academic insights into the mechanisms underlying the acquisition of stem-like plasticity in B-cell lymphomas and emerging targeted therapeutic strategies. The key points are presented below for our readers.
ESMO Insights | Professor Barbara Pistilli: Updated VIKTORIA-1 Results Show Sustained Survival Benefit and Improved Safety with Gedatolisib-Based Combinations in PIK3CA-Mutant Advanced Breast Cancer

ESMO Insights | Professor Barbara Pistilli: Updated VIKTORIA-1 Results Show Sustained Survival Benefit and Improved Safety with Gedatolisib-Based Combinations in PIK3CA-Mutant Advanced Breast Cancer

At the 2026 ESMO Congress, Professor Barbara Pistilli of Gustave Roussy Cancer Center, France, presented updated results from VIKTORIA-1 Study 2 in patients with PIK3CA-mutant disease. The study showed that both the gedatolisib triplet combination (gedatolisib + palbociclib + fulvestrant) and the doublet combination (gedatolisib + fulvestrant) significantly improved progression-free survival (PFS) compared with alpelisib plus fulvestrant, regardless of whether patients had visceral or liver metastases. Based on these findings, Oncology Frontier interviewed Professor Barbara Pistilli at the congress to discuss the subgroup analyses, safety data, and clinical implications of the study.
ESMO Insights | Professor Gustavo Werutsky: lidERA BC PRO Results Show Giredestrant Improves Efficacy While Preserving Quality of Life

ESMO Insights | Professor Gustavo Werutsky: lidERA BC PRO Results Show Giredestrant Improves Efficacy While Preserving Quality of Life

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27 (local time). At the meeting, Professor Gustavo Werutsky of Moinhos de Vento Hospital in Porto Alegre, Brazil, presented patient-reported outcome (PRO) data from the phase III lidERA BC study (Abstract No. 538RO). The study evaluated the efficacy and safety of giredestrant, an oral selective estrogen receptor degrader (SERD), as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative (ER+/HER2−) early breast cancer. The PRO analysis showed that, alongside a significant improvement in invasive disease-free survival (iDFS), giredestrant effectively preserved patients' health-related quality of life (HRQoL) and daily functioning, while significantly reducing the burden of side effects and the risk of treatment discontinuation. Following his presentation, Oncology Frontier invited Professor Gustavo Werutsky for an interview to discuss the key findings and clinical implications of the lidERA BC PRO data, as well as their potential impact on the future landscape of adjuvant endocrine therapy.
Professor Shuiping Yin: New Developments and Individualized Strategies in the Treatment of Advanced Renal Cell Carcinoma

Professor Shuiping Yin: New Developments and Individualized Strategies in the Treatment of Advanced Renal Cell Carcinoma

In the field of urologic oncology, systemic treatment for advanced renal cell carcinoma (RCC) has fully entered the era of targeted therapy combined with immunotherapy (targeted therapy–immunotherapy combinations). However, how to make precise, individualized treatment decisions for patients across different risk groups, and how to select the optimal subsequent-line regimen after treatment failure, remain major clinical challenges. At the recent 2026 CACAGU Academic Conference, Professor Shuiping Yin and Professor Zhaozhao Liang from the Department of Urology, The First Affiliated Hospital of Anhui Medical University, delivered an in-depth presentation entitled Individualized Treatment and Latest Research Advances in Advanced Renal Tumors. This article highlights the key points of their presentation and systematically reviews individualized first-line treatment decisions, investigations of triplet combinations, advances in second-line treatment, and surgical management of complex tumor thrombi.
10th West China Tianfu Academic Conference on Urologic Oncology | Professor Baijun Dong: From AR Inhibition to Combination Strategies Targeting Multiple Pathways—Exploring New Approaches to Overcoming Treatment Resistance in Prostate Cancer

10th West China Tianfu Academic Conference on Urologic Oncology | Professor Baijun Dong: From AR Inhibition to Combination Strategies Targeting Multiple Pathways—Exploring New Approaches to Overcoming Treatment Resistance in Prostate Cancer

The 10th West China Tianfu Academic Conference on Urologic Oncology was held in Chengdu from November 5 to 7, 2026. From conventional androgen receptor (AR) inhibitors to AR degraders, and further to combination strategies targeting AR alongside PARP and AKT inhibitors, pharmacological treatment for prostate cancer is shifting from single-target blockade toward coordinated pathway inhibition. However, treatment resistance remains a central challenge that cannot be overlooked. Against this backdrop, Oncology Frontier – UroStream invited Professor Baijun Dong from Renji Hospital, Shanghai Jiao Tong University School of Medicine, to share his insights into promising directions in AR-targeted drug development, combination treatment strategies, and pathways for the international development of innovative drugs originating in China.
10th West China Tianfu Academic Conference on Urologic Oncology | Professor Fufu Zheng: Focusing on KIM-1 and ctDNA to Explore New Approaches to Precision Diagnosis and Treatment of Renal Cancer

10th West China Tianfu Academic Conference on Urologic Oncology | Professor Fufu Zheng: Focusing on KIM-1 and ctDNA to Explore New Approaches to Precision Diagnosis and Treatment of Renal Cancer

The 10th West China Tianfu Academic Conference on Urologic Oncology was held in Chengdu from November 5 to 7, 2026. To date, renal cancer still lacks a biomarker comparable to PSA. Diagnosis relies on imaging, while postoperative management depends on follow-up, leaving a critical gap in the framework for precise risk stratification. Against this backdrop, Oncology Frontier – UroStream invited Professor Fufu Zheng from the First Affiliated Hospital of Sun Yat-sen University to share his insights on the most pressing biomarker needs in renal cancer, the clinical value of KIM-1 and ctDNA, how biomarkers can be incorporated into risk-stratified treatment, and the pathway from biomarker discovery to standardized clinical implementation.